Ocular Therapeutix (NASDAQ:OCUL) Sets New 12-Month Low – What’s Next?

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) reached a new 52-week low on Friday. The company traded as low as $6.00 and last traded at $6.0540, with a volume of 541,312 shares traded. The stock had previously closed at $6.28.

Top Ocular Therapeutix Stories

Here are a few of the latest stories about OCUL:

• Positive Sentiment: HC Wainwright raised its price target to $28 and retained a Buy rating; RBC Capital also kept its Buy rating, signaling continued analyst optimism. Ocular Therapeutix Stock Gets Price Target Increase from HC Wainwright RBC Capital Keeps Their Buy Rating
• Neutral Sentiment: Although the Phase 3 result is encouraging, another report notes that debate over OCUL’s valuation persists, which may temper enthusiasm about the clinical news. Ocular Therapeutix on Phase 3 AMD Win and Valuation Debate
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple quarters and for FY2026 and FY2027. Its FY2027 loss estimate widened from $1.54 to $1.87 per share, suggesting expectations for near-term profitability have weakened despite the Buy rating.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on OCUL shares. Wall Street Zen cut shares of Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a report on Saturday. UBS Group assumed coverage on shares of Ocular Therapeutix in a report on Sunday, October 11th. They set a “buy” rating and a $14.00 price objective for the company. HC Wainwright boosted their price objective on shares of Ocular Therapeutix from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, November 10th. Needham & Company LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a research report on Monday, October 19th. Finally, Chardan Capital restated a “buy” rating and issued a $23.00 target price on shares of Ocular Therapeutix in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $23.83.

Ocular Therapeutix Stock Down 1.1%

The company has a market cap of $1.37 billion, a P/E ratio of -4.25 and a beta of 1.22. The company has a quick ratio of 13.03, a current ratio of 9.12 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $7.99 and its 200 day moving average is $8.91.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.06). Ocular Therapeutix had a negative net margin of 648.64% and a negative return on equity of 59.95%. The company had revenue of $12.87 million for the quarter, compared to the consensus estimate of $14.27 million. During the same period last year, the business posted ($0.38) EPS. The firm’s revenue was down 11.5% compared to the same quarter last year. As a group, equities analysts anticipate that Ocular Therapeutix, Inc. will post -1.61 earnings per share for the current fiscal year.

Insider Activity

In other Ocular Therapeutix news, insider Todd Anderman sold 11,984 shares of Ocular Therapeutix stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $7.29, for a total value of $87,363.36. Following the transaction, the insider owned 140,484 shares in the company, valued at $1,024,128.36. The trade was a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Peter Kaiser sold 9,990 shares of Ocular Therapeutix stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $7.05, for a total value of $70,429.50. Following the completion of the transaction, the insider owned 254,388 shares in the company, valued at $1,793,435.40. This trade represents a 3.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 98,090 shares of company stock worth $787,920 over the last ninety days. 3.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Ocular Therapeutix

A number of institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC bought a new position in shares of Ocular Therapeutix during the 2nd quarter worth approximately $51,000. Sterling Capital Management LLC boosted its stake in Ocular Therapeutix by 401.7% in the third quarter. Sterling Capital Management LLC now owns 6,612 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 5,294 shares in the last quarter. Root Financial Partners LLC acquired a new stake in Ocular Therapeutix in the third quarter valued at approximately $66,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Ocular Therapeutix in the third quarter worth $86,000. Finally, Trust Co. of Vermont purchased a new position in Ocular Therapeutix in the second quarter worth $112,000. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.